
Peptide therapy has moved from a niche biohacking trend to one of the most requested conversations in medical wellness, and the San Fernando Valley is no exception. Patients ask about it for a wide range of goals: faster recovery from injury or training, support for natural growth hormone production, sexual health, and general vitality as part of a broader longevity plan. But peptide therapy is also one of the most misunderstood corners of medicine right now, partly because the regulatory landscape around it has been shifting rapidly.
At Contour Medical Clinic in Tarzana, peptide therapy is offered as part of a physician-supervised program, built on accurate information, verified sourcing, and realistic expectations rather than hype. This guide covers what peptides actually are, the most commonly used types and what they're used for, the current 2026 regulatory picture, safety considerations, and what a physician-supervised peptide program looks like in practice.
Peptides are short chains of amino acids — smaller and simpler than full proteins — that act as signaling molecules in the body. Many hormones your body already produces, including insulin and growth hormone, are technically peptides. Peptide therapy uses synthetic versions of these molecules, or peptides designed to trigger a specific natural process, to support functions like tissue repair, growth hormone release, metabolic signaling, or immune activity.
The appeal is specificity. Rather than introducing a hormone directly, many therapeutic peptides work by stimulating the body's own production or release of a hormone, which can offer a more physiological, pulsatile pattern than direct hormone replacement alone. This is part of why peptide therapy is often discussed alongside, rather than instead of, treatments like hormone optimization and TRT.
Peptide regulation has changed substantially in recent years, and understanding where things stand matters for your safety as a patient. In 2023, the FDA placed a group of widely used peptides — including BPC-157, TB-500, CJC-1295, and Ipamorelin — on its Category 2 list, which restricted licensed 503A compounding pharmacies from preparing them. That left most clinical peptide programs sourcing from specialized research-grade laboratories that test each batch to pharmaceutical analytical standards, rather than through traditional compounding pharmacies.
In February 2026, HHS announced plans to move a number of these peptides — reportedly including BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, and MOTS-C — back toward Category 1 status, which would restore a legal pathway for compounding pharmacies to prepare them under a valid prescription. As of this writing, the FDA's Pharmacy Compounding Advisory Committee has a meeting scheduled for late July 2026 to formally review several of these substances for compounding eligibility, including BPC-157, KPV, TB-500, and MOTS-C.
What this means practically: even where reclassification moves forward, these remain substances without full FDA drug approval for the conditions they're commonly used for (with a few notable exceptions discussed below). A responsible peptide program will always be upfront with you about which peptides are FDA-approved for a specific indication, which are legally compounded off-label under physician prescription, and which fall into an unregulated gray market that a legitimate medical clinic should never use. This is exactly the kind of nuance worth asking about directly during your consultation.
This is the most established category of peptide therapy. Rather than injecting growth hormone directly, these peptides stimulate the pituitary gland to release more of your body's own growth hormone in a natural, pulsatile pattern.
BPC-157 and TB-500 are frequently discussed for soft tissue recovery, tendon and ligament healing, and gut lining support. Preclinical and early research has explored their role in angiogenesis (new blood vessel formation) and tissue repair pathways. Human clinical trial data remains limited compared to the growth hormone secretagogues, which is an important distinction a responsible provider should walk you through rather than presenting these peptides as more clinically proven than they currently are.
PT-141 works differently from most peptides on this list — instead of triggering a hormone release, it acts on melanocortin receptors in the brain to influence sexual desire and arousal through central nervous system pathways rather than local blood flow. It's FDA-approved for hypoactive sexual desire disorder in premenopausal women and is used off-label in men, often alongside broader hormone optimization or TRT protocols.
A smaller category of peptides, including Thymosin Alpha-1, Semax, and Selank, is used for immune modulation and cognitive support as part of broader longevity medicine protocols. Evidence here is generally earlier-stage than for the growth hormone secretagogues, and these peptides are typically layered in only after core priorities — hormone balance, metabolic health, sleep, and recovery — are addressed.
Peptide therapy is generally considered for adults who have already addressed foundational health factors — sleep, nutrition, stress, and any underlying hormonal imbalances — and are looking for additional, targeted support for recovery, body composition, or vitality. It is not a substitute for treating a diagnosed hormone deficiency; if labs indicate low testosterone or thyroid dysfunction, that is typically addressed directly through hormone optimization or TRT before or alongside peptide protocols. Pregnancy, active cancer, and certain other medical conditions are contraindications for most peptide therapies, which is why a full history and baseline labs come before any prescription.
The safety of peptide therapy depends heavily on three factors: where the peptide comes from, whether a physician is actually overseeing your protocol, and whether you're an appropriate candidate in the first place. Before starting peptide therapy anywhere, it's reasonable to ask:
Common side effects across peptide categories include injection site reactions, water retention, and in some growth hormone secretagogues, mild changes in blood sugar or a temporary increase in hunger. Because this is a fast-evolving regulatory area, we recommend confirming current sourcing and legal status directly with your provider at the time of your consultation rather than relying solely on what you've read online — including this article.
Patients sometimes conflate peptide therapy with testosterone therapy or GLP-1 weight loss medications like semaglutide and tirzepatide, but they work through different mechanisms and address different goals. TRT directly replaces testosterone in men and women with confirmed low levels — you can read our full breakdown in the TRT guide. GLP-1 medications like semaglutide and tirzepatide target appetite and metabolic hormone pathways for weight loss and are FDA-approved for that purpose. Peptide therapy, by contrast, is a broader category most often used to support growth hormone activity, tissue recovery, or targeted physiological signaling, and it frequently complements rather than replaces these other treatments. For patients working on multiple fronts at once, our hormone optimization guide explains how these pieces typically fit together.
It depends on the specific peptide and how it's sourced. FDA-approved peptides like tesamorelin and PT-141 can be prescribed for their approved indications without ambiguity. Other peptides, such as BPC-157 and CJC-1295/Ipamorelin, exist in a more complex regulatory space that has been actively changing throughout 2026. A responsible clinic will explain the current status of any peptide before prescribing it.
This varies significantly by peptide and goal. Growth hormone secretagogues typically require several weeks to months of consistent use before body composition changes become measurable, while some patients report subjective changes in sleep or recovery sooner. Your physician will set realistic timeline expectations based on the specific protocol.
No. Growth hormone secretagogue peptides prompt your own pituitary gland to release more growth hormone; they don't introduce synthetic HGH or anabolic steroids directly. This distinction matters both physiologically and legally, though it doesn't mean these peptides are risk-free or appropriate for everyone.
Yes. Baseline labs help confirm you're a reasonable candidate, rule out contraindications, and give your physician a way to measure whether the protocol is actually working, rather than relying on how you feel alone.
Often, yes. Many patients use peptide therapy alongside hormone optimization or medical weight loss programs as part of a coordinated plan. Your physician will sequence and combine treatments based on your labs and goals rather than starting everything at once.
Peptide therapy can be a genuinely useful tool when it's built on accurate sourcing information, real lab data, and physician oversight — not internet hype. Contour Medical Clinic serves Tarzana, Encino, Woodland Hills, Sherman Oaks, and the greater San Fernando Valley with physician-supervised peptide protocols built around your specific goals and health history.
Schedule your free consultation to discuss whether peptide therapy fits your goals, and get a clear, honest picture of what's currently available and appropriate for you.